Cold and flu will infect up to 25% of the Canadian population each year. Serious complications from influenza (flu) are most likely to occur in individuals with certain pre-existing medical conditions or in those over 65 years of age. Moreover, previously healthy young children may also have hospitalization rates comparable to those among the elderly during the influenza season.¹

Susceptibility to infections depends on numerous variables including the status of the immune system. The goal of a treatment with Engystol® is to activate and support the defense mechanisms of the body, i.e., to strengthen the natural immune response in case of a viral invasion.

Numerous studies document the therapeutic and preventive benefits of the homeopathic preparation Engystol® in cases of infections with or without fever such as bronchitis, herpes, otitis, flu, etc.²,³,⁴,⁷

Engystol® is an immunomodulating medication which has been scientifically proven to significantly reduce the duration and severity of symptoms during an acute viral infection and help protect from subsequent infections.

Benefits of Engystol®
- Scientifically demonstrated efficacy
- On the international market for over 35 years
- May be used for both prevention and treatment of viral infections
- Stimulates the non-specific defense system (immunomodulator)
- Suitable for the entire family
- No known contraindications and very well tolerated
- May be combined to other natural or conventional immunomodulating therapies and medications

Dosage recommendation

<table>
<thead>
<tr>
<th>Situation</th>
<th>Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute (From the onset of symptoms)</td>
<td>1 tablet every 30-60 minutes for a maximum of 12 doses per day or 1 oral vial up to 3 times per day</td>
</tr>
<tr>
<td>General (After the onset of symptoms as well as for prevention and chronic treatment)</td>
<td>1 tablet 3 times daily or 1 oral vial 3-7 times weekly</td>
</tr>
</tbody>
</table>

Allow tablet to dissolve slowly in the mouth or pour content of the ampoule in a small quantity of water, sip slowly and keep in mouth before swallowing.

Note: the above adult dosages should be adapted for children according to their age.

Additional information

Side effects: in very rare cases, skin rashes may occur.

While individual response to Engystol® will vary according to each person’s health status, the severity of the condition being treated, the age, the dosage used, etc., initial benefits may be felt within hours or days. If symptoms persist, worsen, are unidentified or newly occurring, consult a health care practitioner as medical attention may be required. For prevention therapy, the general dosage should be administered in cycles of 1 week on and 1 week off.

Revised: October 2008
Engystol®

Scientifically proven

Antiviral activity
Basic research reveals the antiviral activity of Engystol® against viruses (such as the Influenza, the Herpes Simplex type 1, the Rhinovirus, the Adenovirus Type 5 and the Respiratory Syncytial Virus or RSV). 1,2

Efficacy and tolerability
Studies on Engystol® demonstrate an excellent tolerability and efficacy. Physicians have reported "excellent" to "good" tolerance to the medication for 97% of patients. Engystol® achieved a "good" to "very good" therapeutic result in over 88% of patients suffering from infections with fever, the flu or when used as a preventive measure to activate the immune system.2 As well, the time to first symptomatic improvement was shorter with the administration of Engystol® than it was with conventional medications, in cases of upper respiratory infections associated with the common cold.2

Preventive effect
A study evaluating the prophylaxis effect of Engystol® against influenza demonstrated that treatment with Engystol® reduced the frequency of influenza infections compared to the control group. Moreover, the duration and severity of symptoms was considerably lower in the Engystol® group.3

Mechanism of action
In vitro tests have demonstrated that Engystol® stimulates the phagocytic activity of human granulocytes up to 33%. In other words, Engystol® improves the fighting capacity of white blood cells, which digest microorganisms, by 33%! This effect was further enhanced to 41% by combining Engystol® and Gripp-Heel®.4

Newer research has established that T-lymphocytes (immune cells) respond to the administration of Engystol® by increasing interferon-γ production, which is indicative of the activation of the immune system. Therapy that improves interferon-γ production might be expected to confer benefits to people exposed to infectious agents (flu season).5

References

Engystol®
- Scientifically and clinically proven effective
- For the entire family
- No known contraindications nor medicinal interactions

Heel Canada Inc.
Montreal, Canada
1 888 879-4335 • www.heel.ca

The information contained in this brochure does not replace the advice of a health care practitioner.